Literature DB >> 31571214

Nicotinamide N-methyltransferase in nonmelanoma skin cancers.

Veronica Pompei1, Eleonora Salvolini1, Corrado Rubini2, Guendalina Lucarini3, Elisa Molinelli3, Valerio Brisigotti3, Valentina Pozzi1,4, Davide Sartini1, Anna Campanati3, Annamaria Offidani3, Monica Emanuelli1,4.   

Abstract

BACKGROUND: Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) represent the most common forms of nonmelanoma skin cancers (NMSCs). Although successful treatment of these neoplasms is based on surgical excision, an increasing number of BCCs relapses and many SCCs display high rates of recurrence and metastasis. Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme, which was found to be upregulated in different solid tumours. However, there are no data regarding enzyme expression in NMSCs. The aim of this study was therefore to evaluate the potential involvement of NNMT in BCCs and SCCs.
MATERIALS AND METHODS: Immunohistochemical analyses were carried out on 40 BCC cases and 39 SCC cases, to evaluate enzyme expression in tumour and surrounding healthy margins. Moreover, the relationship between NNMT intratumour levels and clinico-pathological parameters were explored.
RESULTS: Nicotinamide N-methyltransferase was found to be overexpressed in BCCs compared with control tissues, while a significant enzyme downregulation was detected in SCCs with respect to corresponding healthy margins. In addition, NNMT levels were negatively related to aggressiveness of both BCCs (distinguishing between infiltrative and nodular tumours) and SCCs (considering head and neck forms and tumours of the extremities and trunk).
CONCLUSIONS: These evidences seem to demonstrate that the different NNMT dysregulation detected in BCC and SCC may be the result of important biological traits distinctively characterizing these two forms within NMSCs. In addition, enzyme levels seem to be inversely correlated with tumour aggressiveness, thus suggesting the potential suitability of the enzyme as a prognostic biomarker for both neoplasms.
© 2019 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Nicotinamide N-methyltransferase; basal cell carcinoma; immunohistochemistry; nonmelanoma skin cancer; squamous cell carcinoma; tumour biomarker

Mesh:

Substances:

Year:  2019        PMID: 31571214     DOI: 10.1111/eci.13175

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  4 in total

1.  Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer.

Authors:  Makiko Ogawa; Atsushi Tanaka; Kei Namba; Jinru Shia; Julia Y Wang; Michael H A Roehrl
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

Review 2.  Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms.

Authors:  Valentina Pozzi; Roberto Campagna; Davide Sartini; Monica Emanuelli
Journal:  Biomolecules       Date:  2022-08-24

Review 3.  Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.

Authors:  Toshihiko Hoashi; Naoko Kanda; Hidehisa Saeki
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

4.  Nicotinamide N-Methyltransferase Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer.

Authors:  Miaowei Wu; Weilei Hu; Guosheng Wang; Yihan Yao; Xiao-Fang Yu
Journal:  Front Genet       Date:  2020-10-28       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.